Paik and colleagues analyzed HER2 expression on tumor samples from 1355 of 2194 (62%) patients enrolled on the NSABP B15 study in which patients with LN+ breast cancer received adjuvant therapy with either AC, CMF, or AC→CMF74. Here, ERBB2 is linked to neoplasm.